Furthermore, <b>15</b> demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model.
Recent data have demonstrated that triple negative breast cancer (TNBC) with high glucocorticoid receptor (GR) expression are associated to therapy resistance and increased mortality.
Herein, p-Ser134 GR was quantified in human primary breast tumors (<i>n</i> = 281) and the levels of p-GR were increased in triple-negative breast cancer (TNBC) relative to luminal breast cancer.
A novel immunohistochemistry (IHC) based assay has been previously developed and validated in order to assess GR immunoreactivity in triple-negative breast cancer.
Primary TNBC tumor explants or cell lines treated with the GR ligand dexamethasone exhibited robust induction of Brk mRNA and protein that was HIF1/2-dependent.